Physician profile
Michelle Caster
NPI 1235519166
$924.40
in general payments reported to CMS, 2019-2025
14 companies · $488 in 2025
The $488 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $15.90 · 2023: $30.59 · 2024: $390 · 2025: $488.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $909.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $908.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $155.37 | 2024-2025 | Ozempic, Rybelsus |
| Gilead Sciences, INC. | $129.15 | 2025 | Biktarvy |
| Viiv Healthcare Company | $125.53 | 2019-2025 | Dovato |
| Astellas Pharma US INC | $118.28 | 2024-2025 | Veozah |
| Merck Sharp & Dohme LLC | $68.38 | 2024-2025 | Gardasil 9, Vaxneuvance, Capvaxive |
| Abbott Laboratories | $62.61 | 2024-2025 | Freestyle Libre 3 |
| Lilly USA, LLC | $55.92 | 2023-2025 | Mounjaro, Zepbound |
| Exact Sciences Corporation | $50.55 | 2023-2025 | Cologuard Collection Kit |
| Xeris Pharmaceuticals, INC. | $41.42 | 2024-2025 | Gvoke Hypopen |
| E.R. Squibb & Sons, L.L.C. | $36.19 | 2024 | Camzyos, Eliquis |
| Janssen Pharmaceuticals, INC | $24.52 | 2024 | Spravato |
| Novartis Pharmaceuticals Corporation | $21.44 | 2025 | |
| Amgen INC. | $18.45 | 2025 | Repatha |
| Sumitomo Pharma America, INC. | $16.59 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Caster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.